Tropical Journal of Pharmaceutical Research August 2024; 23 (8): 1359-1364 ISSN: 1596-5996 (print); 1596-9827 (electronic)

> Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v23i8.17

Original Research Article

Efficacy of triple therapy inhalers in acute exacerbations of chronic obstructive pulmonary disease

Weibiao Wang*, Hong Teng

Respiratory Medicine, Shaoxing Second Hospital Medical Community General Hospital, Shaoxing 312000, China

*For correspondence: Email: Wangweibiao202205@163.com

Sent for review: 19 September 2023

Revised accepted: 24 July 2024

Abstract

Purpose: To evaluate the efficacy of triple inhaled therapy, a combination of inhaled glucocorticoids, long-acting muscarinic antagonists, and long-acting β^2 agonists in managing acute exacerbations of chronic obstructive pulmonary disease (COPD).

Methods: Medical data of 100 patients with acute exacerbation of COPD admitted to Shaoxing Second Hospital, Shaoxing, China between January 2020 to December 2022 was collected and retrospectively analyzed. The patients were randomized into control (n = 50) and study groups (n = 50). Control group received budesonide/formoterol inhalers while the study group received triple inhaled therapy (budesonide/glycopyrronium/formoterol inhalers). Arterial blood gas, pulmonary function, immune function, adverse effects, and efficacy were evaluated.

Results: The study group exhibited significantly higher pH, partial pressure of arterial oxygen (PaO₂), and lower partial pressure of carbon dioxide (PaCO₂) compared to control group (p < 0.001). Furthermore, the study group showed significantly higher levels of pulmonary function and immune function indices compared to control group (p < 0.001). There was no significant difference in incidence of adverse reactions between the two groups (p > 0.05). The study group was associated with higher clinical efficacy compared to the control group (p < 0.05).

Conclusion: Triple inhaled therapy significantly alleviates the clinical symptoms of patients with COPD and enhances pulmonary and immune functions. Future studies should cover a larger and more diverse group of participants for broader validity.

Keywords: Triple inhaled therapy, COPD, Acute exacerbation, Budesonide, Glycopyrronium bromide, Formoterol inhaler

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, Web of Science, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a common clinical condition with the third highest mortality worldwide. This disease increases pulmonary airway resistance and disrupts gas exchange, resulting in long-term chronic hypoxia. The underlying etiology of COPD remains poorly understood, and currently, there are no highly effective targeted drugs available for clinical use, posing an extremely serious threat to life and health [1-3]. The standard pharmacological treatment for COPD typically involves a combination of inhaled glucocorticoids and long-acting $\beta 2$ agonists [4].

Several studies have shown that budesonide and formoterol inhalers can enhance respiratory function, reduce the release of inflammatory mediators, and improve lung function in patients with COPD within a short time [5]. Previous studies have demonstrated that triple-inhaled therapy with glucocorticoids, long-acting muscarinic antagonists (LAMA) and long-acting β2 agonists (LABA) reduces the risk of acute exacerbations of COPD [6]. Thus, this present study was aimed at evaluating the efficacy of inhaled triple therapy (budesonide/alvcopyrronium bromide/formoterol inhalers) in managing acute exacerbation of COPD.

METHODS

Patient characteristics

Medical data of 100 patients with acute exacerbations of COPD admitted to Shaoxing Second Hospital, Shaoxing, China between January 2020 to December 2022 were collected and retrospectively analyzed. The patients were randomized equally into study and control groups. Study group received triple inhaled therapy comprisina of budesonide/glycopyrronium bromide/formoterol while control group received a combination of budesonide and formoterol inhalers. This study was approved by the ethics committee of Shaoxing Second Hospital Medical Community General Hospital (approval no. 2024-028) and complied with the Declaration of Helsinki [7].

Inclusion criteria

Patients who met the diagnostic criteria in the 2001 Guidelines for the Diagnosis and Management of COPD developed by Barber *et al* [8], history of at least one acute exacerbation of COPD in the previous year, and who were fully informed about the study procedures and signed the informed consent form.

Exclusion criteria

Patients with other serious organ diseases, psychiatric problems that interfere with normal communication, patients at risk of inhalation, diagnosed with asthma, patients with poor compliance, and contraindications or allergies to the study medications.

Treatments

After admission, patients in both groups were treated with anti-infective treatment, expectorants oxygen support, and nebulized terbutaline hydrochloride solution (1 mL twice daily). During this period, routine physiological data, such as blood pressure, heart rate, pulse rate, and oxygen saturation, were closely monitored. Adverse symptoms were resolved promptly, and oxygen saturation was maintained at > 90 %. Control received group ma 2 budesonide/formoterol inhalers (2 puffs) twice daily while study received group budesonide/glycopyrronium /formoterol inhalers (2 puffs) twice daily. The drug was administered solely via transoral inhalation. In case of a missed dose, it was important to replenish it as soon as possible and follow the regular medication schedule for the next dose. Double doses were not allowed to compensate for missed doses. Patients in both groups were treated for 20 days.

Evaluation of parameters/indices

Arterial blood gas indices

The pH, arterial oxygen partial pressure (PaO₂), and carbon dioxide partial pressure (PaCO₂) were measured using a GEM3000 blood gas analyzer (Beckman, USA, Food & Drug Administration, 2008, No. 2401894), and values were compared before and after treatment in both groups.

Pulmonary function

Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and FEV1/FVC were measured using an FGC-A+ pulmonary function tester (Anhui Institute of Electronic Science, Anhui Machinery Note approval no. 20172210164), and values compared before and after treatment in both groups.

Immune function

The T-lymphocyte (CD3+, CD4+, CD4+/CD8+) were compared before and after treatment using a flow cytometer (Eisen Bio Hangzhou Co., Ltd., Zhejiang Food and Drug Administration Arms Quorum 2014 no. 2400581).

Adverse effects

Adverse reactions including dry and bitter throat, dry nose and diarrhea, were observed. The number of patients experiencing adverse reactions was recorded to calculate the ARR.

Overall efficacy

Efficacy was classified as markedly effective (clinical symptoms and coughing frequency were

significantly reduced, as well as dyspnea and other phenomena); effective (clinical symptoms, coughing frequency and dyspnea were reduced); ineffective (a state that did not meet the above criteria).

Statistical analysis

The data were analyzed using Statistical Package for Social Sciences (SPSS version 20.0, IBM, Armonk, NY, USA), and Graph Pad Prism 7 (GraphPad Software, San Diego, USA) was employed to generate the required visualizations. Measurement data were expressed as mean \pm standard deviation (SD) and compared using t-test. Count data were expressed as frequency and percentages (%) and compared using the chi-square test. *P* < 0.05 was considered statistically significant.

RESULTS

Baseline characteristics

There were no significant differences in baseline characteristics of the patients in both groups (p > 0.05; Table 1).

Arterial blood gas

Study group exhibited significantly higher pH values and PaO₂ and lower PaCO₂ compared to control group (p < 0.001; Table 2).

Pulmonary function

Patients with triple therapy inhalers had significantly higher levels of pulmonary function compared to control group (p < 0.001; Table 3).

Table 1: Baseline	characteristics	(n = 50 in e	each group)
-------------------	-----------------	--------------	-------------

Group	Study group	Control group	X²/t	P-value
Sex			0.034	0.855
Male	33	22		
Female	17	18		
Age (years)				
Range	44-74	43-74		
Mean age	65.21±12.24	65.22±12.58	0.004	0.997
Heart rate	124.20±15.21	124.52±15.89	0.113	0.911
Diabetes	32	30	0.223	0.637
Hypertension	11	12	0.086	0.769
Coronary heart disease	7	8	0.076	0.783
Duration of disease (years)				
Range	3-21	3-20		
Mean duration of disease	7.25±0.89	7.32±0.57	0.513	0.609

Some values are expressed as mean ± standard deviation

Table 2: Arterial blood gas (n = 50)

Group				
Study		Control		
Before treatment	After treatment	Before treatment	After treatment	
7.20±0.21	7.42±0.12*	7.21±0.20	7.29±0.13**	
53.12±14.23	83.88±15.41*	53.22±14.56	70.21±14.23**	
80.12±11.24	55.24±9.80*	80.13±11.25	65.12±9.82**	
	Study Before treatment 7.20±0.21 53.12±14.23 80.12±11.24	StudyBefore treatmentAfter treatment7.20±0.217.42±0.12*53.12±14.2383.88±15.41*80.12±11.2455.24±9.80*	StudyControlBefore treatmentAfter treatmentBefore treatment7.20±0.217.42±0.12*7.21±0.2053.12±14.2383.88±15.41*53.22±14.5680.12±11.2455.24±9.80*80.13±11.25	

*P < 0.05 vs before treatment, **p < 0.05 vs study group. Values are presented as mean \pm SD

Table 3: Pulmonary function (n = 50)

Parameter	Group				
	Study		Control		
	Before treatment	After treatment	Before treatment	After treatment	
FEV₁(L)	1.11±0.12	1.81±0.15*	1.12±0.13	1.65±0.14**	
FVC (L)	2.01±0.15	2.41±0.12*	2.02±0.12	2.19±0.14**	
FEV1/FVC (%)	55.45±3.59	79.12±5.32*	55.46±3.60	72.56±5.46**	

*P < 0.05 vs before treatment, **p < 0.05 vs study group. Values are presented as mean ± SD. Forced expiratory volume in one second (FEV1), forced vital capacity (FVC)

Immune function

Study group showed significantly higher levels of CD4+/CD8+, CD3+ and CD4+ compared to control group (p < 0.001; Figure 1).




Figure 1: Immune function Note: *P < 0.001 vs study group

Adverse effects

In the study group, there was 1 case (1.7 %) of dry and bitter throat, 1 case (1.7 %) of dry nose, and 2 cases (3.3 %) of diarrhea, with an ARR of 6.7 %. In the control group, there were 3 cases of dry and bitter throat (5.0 %), 1 case of dry nose (1.7 %), and 2 cases of diarrhea (3.3 %), with an ARR of 10 %. There was no significant difference in adverse reaction rate (ARR) between study and control groups (P = 0.509, Figure 2).




Figure 2: Adverse reaction rate n (%)

Clinical efficacy

Study group was associated with a higher clinical efficacy compared to control group (p < 0.05; Table 4).

DISCUSSION

Patients with COPD frequently experience symptoms of hypoxia, malnutrition, and immune deficiency, with severe diaphragmatic fatigue, further worsening pulmonary dysfunction. Therefore, symptom management, risk reduction, and improvement of body function are paramount in managing patients with acute exacerbations of COPD [9-12]. Dual therapy with LABA and glucocorticoids are conventional drugs for COPD treatment with antispasmodic and bronchodilating effects, which enhance short-term respiratory function. However, long-term maintenance therapy leads to poor disease control, mild deterioration, and poor patient compliance. Long-acting muscarinic antagonist (LAMA), such as inhaled glycopyrronium bromide, binds to muscarinic receptors with high affinity and features an extended dissociation curve. This agent brings about long-term bronchial dilation in patients with COPD, further enhancing immune capacity and tolerance to hypoxia. The efficiency of triple inhaled therapy outperforms the two-drug combination [13-16].

In this study, improvement in pulmonary function indices (FEV1, FVC, and FEV1/FVC) in study group was significantly higher after treatment compared to control group. It therefore indicates that budesonide, glycopyrronium and formoterol effectively improve lung function and circulation capacity. As a result, hypoxia and carbon dioxide retention were more effectively reduced, leading to significantly better arterial blood gas in study group compared to control group after treatment. Clinical trials have shown that budesonide/glycopyrronium/formoterol triple therapy reduced the incidence of acute exacerbations in moderate and even severe COPD, prolonged duration of exacerbations, improved lung function, symptom relief, and quality of life [5,16]. These findings were consistent with the results of the present study. In addition, COPD is associated with an increase in the frequency of anaerobic enzymes in Tlymphocytes, leading to immune dysfunction and increased risk of infection.

Group	Markedly effective	Effective	Ineffective	Total efficacy
Study	23(46.0)	25(50.0)	2(4.0)	48(96.0)
Control	13(26.0)	27(54.0)	10(20.0)	40(80.0)
χ^2	3.525	0.134	5.926	5.926
<i>P</i> -value	0.060	0.715	0.015	0.015

Table 4: Clinical efficacy n (%)

Therefore, enhancement of immune function may provide prognostic benefits for patients [17-19]. In this study, immune function in study group was significantly higher compared to control group (p < 0.001). This suggested that triple-inhaled therapy enhances immune function in patients with COPD, prevents further disease inhibits aggregation deterioration, of inflammatory cells, and exerts anti-inflammatory effects. Previous studies have revealed that the combination of these three drugs enhances immune function [20], which is in tandem with this study. In addition, studies have shown that more than 70 % of COPD patients treated with a combination of budesonide, glycopyrronium and formoterol inhalers experienced no acute exacerbations within 1 year. Hence, the Global COPD has recommended Initiative for maintenance therapy with triple inhaled therapy for severe and extremely severe COPD. However, given the complexity of COPD management, which often involves frequent episodes, the choice of treatment should be based on the patient's clinical symptoms, habits, preferences, and inhaler characteristics. Rational selection of triple-inhaled therapy improves clinical efficacy while ensuring drug safety and patient tolerability.

Limitations of this study

Limitations of this study include a potentially limited sample size and the absence of long-term follow-up, which significantly impact the validity of the findings. It is crucial to conduct longitudinal studies over extended periods to evaluate the long-term efficacy and safety of triple inhaled therapy in COPD management.

CONCLUSION

Triple-inhaled therapy comprising budesonide, formoterol glycopyrronium and enhances pulmonary function, and improves immune responses, with lower incidence of adverse effects and higher efficacy. These findings provide valuable insights into the potential of triple-inhaled therapy as a comprehensive that addresses treatment approach both respiratory symptoms and underlying immune challenges in COPD patients. Future studies should cover a larger and more diverse group of participants, to ensure that the findings are more representative.

DECLARATIONS

Acknowledgements

None.

Funding

None provided.

Ethical approval

None provided.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. WW conceived and designed the study, and drafted the manuscript. HT collected, analyzed and interpreted the experimental data. Both authors revised the manuscript for important intellectual content. Both authors read and approved the final manuscript for publication.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ 4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/rea d), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

- Tee A, Chow WL, Burke C, Guruprasad B. Costeffectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: A LANTERN population analysis from Singapore. Singapore Med J 2018; 59(7): 383-389.
- 2. Bell CF, Coutinho AD, Farrelly E, Lokhandwala T, Landsman-Blumberg P. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50mcg combination versus tiotropium bromide 18mcg as initial maintenance

treatment for chronic obstructive pulmonary disease in managed care. J Med Econ 2018; 21(6): 629-638.

- Liu Y, Zhang C, Chen X. Effects of combination treatment with theophylline sustained-release tablets and thymalfasin on pulmonary function, immunity, and inflammation in elderly patients with chronic obstructive pulmonary disease and respiratory failure. Trop J Pharm Res 2023; 22: 167-174.
- Lakhotia B, Mahon R, Gutzwiller FS, Danyliv A, Nikolaev I, Thokala P. Modelling the cost-effectiveness of indacaterol/glycopyrronium versus salmeterol/fluticasone using a novel Markov exacerbation-based approach. Int J Chron Obstruct Pulmon Dis 2020; 15: 787-797.
- Wedzicha JA, Singh D, Tsiligianni I, Jenkins C, Fucile S, Fogel R, Shen S, Goyal P, Mezzi K, Kostikas K. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. Respir Res 2019; 20(1): 4.
- Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, Hamann AM, Backer A, Olsson P, Kostikas K, et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial. Respirol 2018; 23(12): 1152-1159.
- World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-2194.
- Barberà JA, Peces-Barba G, Agustí AG, Izquierdo JL, Monsó E, Montemayor T, Viejo JL, Sociedad Española De Neumología y Cirugía Torácica (SEPAR). Clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease. Arch Bronconeumol 2001; 37(6): 297-316.
- Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2018; 12: 1753465818755091.
- Moretz C, Sharpsten L, Bengtson LG, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. Int J Chron Obstruct Pulmon Dis 2019; 14: 1721-1737.

- Mirsadraee M, Ghaffari S, Saeedi P. Effect of Salmeterol-Fluticasone Combination and Tiotropium on Clinical and Physiological Improvement of Bronchial Anthracofibrosis: a Double Blind Randomized, Cross Over, Placebo Controlled, Clinical Trial. Tanaffos 2018; 17(3): 163-171.
- Skoupa J, Kasak V, Klimes J, Valena T. Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD—A Cost-Effectiveness Analysis in the Czech Republic. Value Health Reg Issues 2018; 16: 112-118.
- Blair HA. Fluticasone propionate/salmeterol (Wixela Inhub) dry-powder inhaler in asthma and COPD: a profile of its use in the USA. Drugs & Therapy Perspectives 2019; 35(12): 583-591.
- Ielpo A, Crisafulli E. When two drugs are better than three: Re-modulating the therapeutic plan of a chronic obstructive pulmonary disease patient. Respiration 2018; 95 Suppl 1(1): 6-10.
- Chen Z, Qian X. Effect of montelukast/budesonide formoterol powder inhalation in chronic obstructive pulmonary disease. Trop J Pharm Res 2022; 21: 1037-1043.
- 16. Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, Naya IP, Boucot IH, Lipson DA, Compton C, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomized trial. Respir Res 2019; 20(1): 238.
- Masureel M, Zou Y, Picard LP, Van der Westhuizen E, Mahoney JP, Rodrigues JPGLM, Mildorf TJ, Dror RO, Shaw DE, Bouvier M, et al. Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist. Nat Chem Biol 2018; 14(11): 1059-1066.
- 18. Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, Van Zyl-Smit RN. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study. Int J Chron Obstruct Pulmon Dis 2018; 13: 3923-3936.
- Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel-group, randomized controlled trial. Lancet 2018; 391(10125): 1076-1084.
- 20. Poole N. Can Chinese herbal decoction cure chronic obstructive pulmonary disease? Tanaffos 2019.